Contact us if you would like more information about IntegraGen and our efforts.
18 April 2019 IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019. Click here to view press release. 15 March 2019 05 March 2019 IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy. 09 January 2019 IntegraGen announced today its unaudited annual sales revenue for 2018. 12 November 2018 IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools. 21 October 2018 Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) » 20 September 2018 IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018. 19 September 2018 IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…) » 06 September 2018 GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…) » 04 September 2018 IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…) » IntegraGen Reports 2018 Annual Results
IntegraGen to present at 6th annual Portzamparc MidCap Conference – April 10, 2019
Come and meet us at the #ConfMidCap2019 @Portzamparc, April 10th!
IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test
IntegraGen Reports Revenue of €6.9 million for 2018 (+11%) and Cash Position of €4.0 million
IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers
IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018
IntegraGen Reports Financial Results for 1st Half of 2018
IntegraGen nominated for a 2018 PrixGalien MedStartup Award
IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.
IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research
